HEALTH: Answers to Questions About the COVID Booster Recommendations
| | | | | | | | | | | | | | | | | | | | | | | |

HEALTH: Answers to Questions About the COVID Booster Recommendations

Oct. 27, 2021 — Now that federal regulators have issued guidelines on booster doses for the COVID-19 vaccine, many people have many questions. Here are some answers.Who Is Eligible for a Booster Dose Now?As of Oct. 20, the FDA has granted emergency use authorization for Moderna, Pfizer, and Johnson & Johnson vaccine booster doses for…

HEALTH: FDA Panel Backs Second Shot for Those Who Got J&J Vaccine
| | | | | | | | | | | | | | | | | | | | | | | |

HEALTH: FDA Panel Backs Second Shot for Those Who Got J&J Vaccine

Oct. 15, 2021 — A FDA advisory committee on Friday voted 19-0 to authorize second doses of the Johnson & Johnson COVID-19 vaccine in an effort to boost immunity. This was the second vote in two days to support a change to the COVID vaccine timeline. In its vote, the committee said that boosters could…

BUSINESS: Janssen Announces Phase IIb Data. This Data Shows That Janssen’s Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Diseases In Older Adults
| | | | | | | | | | | | | | | | | | | | | | | | | | | |

BUSINESS: Janssen Announces Phase IIb Data. This Data Shows That Janssen’s Investigational RSV Adult Vaccine Provided 80% Protection Against Lower Respiratory Diseases In Older Adults

RARITAN, N.J., Oct. 2, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV, demonstrating vaccine efficacy of 80 percent (CI, 52.2-92.9%) in adults aged 65 and older. The study…

BUSINESS: Johnson & Johnson Announces Real-World Evidence And Phase 3 Data Confirming Strong And Long-Lasting Protection Of Single-Shot COVID-19 Vaccine In The U.S.
| | | | | | | | | | | | | | | | |

BUSINESS: Johnson & Johnson Announces Real-World Evidence And Phase 3 Data Confirming Strong And Long-Lasting Protection Of Single-Shot COVID-19 Vaccine In The U.S.

NEW BRUNSWICK, N.J., Sept. 21, 2021 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) (the Company) today announced new data reinforcing the strong and long-lasting protection of its COVID-19 vaccine. New data also showed that protection against COVID-19 increases when a booster shot of the Johnson & Johnson vaccine is administered. The safety profile of the vaccine…

BUSINESS: New Data On RYBREVANT(R) (Amivantamab-Vmjw) In Combination With Lazertinib Show Early Activity In Patients With Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib And Platinum-Based Chemotherapy
| | | | | | | | | | | | | | | |

BUSINESS: New Data On RYBREVANT(R) (Amivantamab-Vmjw) In Combination With Lazertinib Show Early Activity In Patients With Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib And Platinum-Based Chemotherapy

RARITAN, N.J., Sept. 19, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose…

BUSINESS: RYBREVANT(R) (Amivantamab-Vmjw) Provides Higher Activity And Longer Duration Of Response When Used In Combination With Lazertinib In Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
| | | | | | | | | | | | | | |

BUSINESS: RYBREVANT(R) (Amivantamab-Vmjw) Provides Higher Activity And Longer Duration Of Response When Used In Combination With Lazertinib In Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib

RARITAN, N.J., Sept. 19, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.1 The analysis showed higher…

BUSINESS: Janssen Presents Results From Phase 1b/2 NORSE Study In Patients With Metastatic Or Locally Advanced Urothelial Carcinoma Treated With BALVERSA® (Erdafitinib) In Combination With Cetrelimab, A PD-1 Inhibitor
| | | | | | | | | | | | | | | |

BUSINESS: Janssen Presents Results From Phase 1b/2 NORSE Study In Patients With Metastatic Or Locally Advanced Urothelial Carcinoma Treated With BALVERSA® (Erdafitinib) In Combination With Cetrelimab, A PD-1 Inhibitor

RARITAN, N.J., Sept. 17, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast…

| | | |

BUSINESS: ERLEADA (r) (apalutamide). Oral presentations demonstrate the importance of Prostate Specific Antigens (PSA) and show strong patient adhesion rates

RARITAN, N.J., Sept. 11, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer…

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

The US worried about vaccine tourists. Now it’s encouraging them.

Like many vaccine tourists, “Alex” doesn’t want you to know his real name.  The British expat arrived on a red-eye flight from his home in Nairobi, Kenya, at New York’s John F. Kennedy International Airport on Friday, May 21, with the intention of staying just a few days—more than enough time, he hoped, to get…

Worst of COVID may be yet to come in Africa
| | | | | | | | | | | | | | | | | | | | |

Worst of COVID may be yet to come in Africa

Photo: NIAID via Flickr For global health reporters watching for the next COVID-19 story, health officials warn that all eyes should remain on Africa, where COVID-19 could spread uncontrollably. Though the surge of COVID-19 cases that occurred in South Africa earlier in 2021 has somewhat eased, there is potential for new variants of the SARS-CoV-2…

Washington state plans to fully reopen by June 30 as governor pushes COVID vaccine incentives
| | | | | | | | | | | | | | | | | |

Washington state plans to fully reopen by June 30 as governor pushes COVID vaccine incentives

Washington Gov. Jay Inslee, without his usual mask, on Thursday during a news conference. (Twitter screen grab) Washington state will move to fully reopen and lift restrictions put on the economy by COVID-19 by June 30, Gov. Jay Inslee announced on Thursday. The move comes as new cases of COVID-19 in the state are declining,…

| | | | | | | | | | | | | | | | | | | | | | | |

Five reasons why you don’t need to panic about coronavirus variants

On May 10, the World Health Organization added a new virus to its list of covid-19 variants of global concern. The variant, B.1.617, is being blamed for the runaway infections in India. It is the fourth addition to a list that also includes variants first identified in the UK, South Africa, and Brazil. “There is some…

| | | | | | | | | | | | | | | | | | | | | | |

Why mixing vaccines could help boost immunity

A dozen covid-19 vaccines are now being used around the world. Most require two doses, and health officials have warned against mixing and matching: the vaccines, they argue, should be administered the way they were tested in trials. But after emerging concerns about the very rare risk of blood clots linked to the Oxford-AstraZeneca vaccine,…

| | | | | | | | | | | | | | | | | | | | | |

The J&J vaccine is back. Next comes trust.

Last week US regulators recommended resuming use of the Johnson & Johnson vaccine, after deciding that a side effect involving blood clots was too rare to justify continuing the brief suspension they had imposed: there were just 15 reported instances out of 8 million doses. But even though the pause lasted just 11 days, it…

‘A false sense of security’: Health experts differ on whether CDC’s new mask rules are beneficial
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

‘A false sense of security’: Health experts differ on whether CDC’s new mask rules are beneficial

Dr. Umair Shah, Washington state’s Secretary of Health (left), and Dr. Ali Mokdad, a professor with the Institute for Health Metrics and Evaluation (IHME), a research center at the University of Washington. In the U.S., some 43% of the population has received at least one COVID-19 vaccination dose. And as these numbers rise, the Centers…

| | | | | | | | | | | | | | | | | | | | | |

Brave Care raises $10M to expand its primary and urgent care clinics for kids, grow remote services

A Brave Care provider in Portland, Ore. treating a family. (Ali Rae / Brave Care Photo) New funding: Portland, Ore.-based pediatric health startup Brave Care raised a $10 million Series A round. How it works: Brave Care is akin to ZOOM+Care clinics but specifically targets kids. The startup offers around-the-clock remote care through an app and…

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

How a tiny media company is helping people get vaccinated

More than 132 million people in the US have received at least one dose of a covid-19 vaccine, and as of this week, all Americans over 16 are eligible. But while the US has vaccinated more people than any other country in the world, vulnerable people are still falling through the cracks. Those most affected…

| | | | | | | | | | | | | | | | | |

The Wonders of mRNA Vaccines that are Leading the Coronavirus Counterattack

Hailed for ushering in a “new era of vaccinology” long before the coronavirus resulted in a worldwide pandemic, messenger RNA (mRNA) vaccines were rolled out by Pfizer/BioNTech and Moderna in December 2020 to combat COVID-19. These vaccines are, indeed, among the safest vaccines ever developed. The Wonders of mRNA Vaccines These incredible vaccines trigger an…

| | | | | | | | | | | | | |

Why is it so hard to review the Johnson & Johnson vaccine? Data.

The future of the single-shot Johnson & Johnson covid vaccine remains in limbo after an advisory panel recommended taking a deeper look into reports of rare—and sometimes fatal—side effects. The US Centers for Disease Control and the Food and Drug Administration advised suspension of the Johnson & Johnson vaccine on Tuesday, after reports that six…

| | | | | | | | | | | | | | | | |

The US says not to give Johnson & Johnson vaccines after a woman died from a rare blood clot

The US took the dramatic step of recommending that health-care providers stop giving people the Johnson & Johnson vaccine against covid-19 after six women who received it developed serious blood clots and one died. The US Food and Drug Administration described its action as a temporary halt to give regulators time to understand the apparent…

End of content

End of content